The firm advised Valkyrie Clinical Trials (Valkyrie) in its strategic partnership with Flourish Research (Flourish), a leading multi-site clinical trial organization. Flourish's investment marks a significant expansion of its presence in oncology research and strengthens its footprint in Southern California. Valkyrie Clinical Trials, founded by Dr. David Berz and operating three sites in Los Angeles, provides cutting-edge cancer therapies and access to more than 200,000 cancer patients through a diverse referral network.
This strategic partnership will enable Valkyrie to accelerate growth and broaden access to innovative oncology trials by leveraging Flourish’s national network and infrastructure. The collaboration also provides Flourish with deep expertise and comprehensive access to the oncology sector, supporting its continued nationwide expansion and commitment to developing advanced cancer treatments.
The Sheppard Mullin deal team was led by partner Aytan Dahukey and associates Karl Buhler and Bryan Lanfranco Ferreyra.
Read the press release here.